Clinical Trial Update: Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA [Phase 2]

View source ↗

Summary

Phase 2 pediatric study evaluating efficacy and safety of narsoplimab in high-risk hematopoietic stem cell transplantation–associated thrombotic microangiopathy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Microangiopathy

Drugs mentioned

• Narsoplimab (narsoplimab)

Snippet

Sponsor: Omeros Corporation | Conditions: Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation | Phase 2 | Status: RECRUITING